
MSCI Europe Pharmaceuticals, Biotechnology and Life Sciences Index (USD)

The MSCI Europe Pharmaceuticals, Biotechnology and Life Sciences Index is designed to capture the large and mid cap segments across 15 Developed Markets (DM) countries in Europe*. All securities in the index are classified in the Pharmaceuticals, Biotechnology and Life Sciences industry group (within the Health Care sector) as per the Global Industry Classification Standard (GICS®).

For a complete description of the index methodology, please see Index methodology - MSCI.

CUMULATIVE INDEX PERFORMANCE — GROSS RETURNS (USD) (JUN 2010 – JUN 2025)



ANNUAL PERFORMANCE (%)

Ph	MSCI Europe armaceutical liotechnology & Life Sciences	s, MSCI Europe	MSCI ACWI
2024	-2.90	2.43	18.02
2023	11.90	20.66	22.81
2022	-4.24	-14.53	-17.96
2021	19.16	16.97	19.04
2020	6.53	5.93	16.82
2019	30.62	24.59	27.30
2018	-2.53	-14.32	-8.93
2017	18.09	26.24	24.62
2016	-12.05	0.22	8.48
2015	3.17	-2.34	-1.84
2014	5.38	-5.68	4.71
2013	33.78	25.96	23.44
2012	20.51	19.93	16.80
2011	11.32	-10.50	-6.86

INDEX PERFORMANCE - GROSS RETURNS (%) (JUN 30, 2025)

FUNDAMENTALS (JUN 30, 2025)

					ANNUALIZED								
	1 Mo	3 Мо	1 Yr	YTD	3 Yr	5 Yr	10 Yr _{De}	Since ec 30, 1994	Div Yld (%)	P/E	P/E Fwd	P/BV	
MSCI Europe Pharmaceuticals, Biotechnology & Life Sciences	0.11	2.69	-8.33	8.13	6.09	6.49	6.11	9.58	2.82	16.01	13.38	3.82	
MSCI Europe	2.08	11.80	19.13	23.69	17.95	13.08	7.43	7.84	3.13	15.91	14.28	2.13	
MSCI ACWI	4.53	11.69	16.69	10.33	17.91	14.18	10.55	8.40	1.81	21.99	18.66	3.29	

INDEX RISK AND RETURN CHARACTERISTICS (JUN 30, 2025)

		ANNUALIZED STD DEV (%) 2		SHARPE RATIO 2,3				MAXIMUM DRAWDOWN		
	Turnover (%) ¹	3 Yr	5 Yr	10 Yr	3 Yr	5 Yr	10 Yr	Since Dec 30, 1994	(%)	Period YYYY-MM-DD
MSCI Europe Pharmaceuticals, Biotechnology & Life Sciences	2.02	15.62	15.53	14.72	0.17	0.30	0.34	0.52	42.06	2007-04-20-2009-03-06
MSCI Europe	3.42	16.52	17.60	16.47	0.81	0.63	0.40	0.37	62.72	2007-10-31-2009-03-09
MSCI ACWI	2.54	14.76	15.37	14.91	0.89	0.76	0.61	0.43	58.06	2007-10-31-2009-03-09

¹ Last 12 months ² Based on monthly gross returns data ³ Based on NY FED Overnight SOFR from Sep 1 2021 & on ICE LIBOR 1M prior that date

The MSCI Europe Pharmaceuticals, Biotechnology and Life Sciences Index was launched on Sep 15, 1999. Data prior to the launch date is back-tested test (i.e. calculations of how the index might have performed over that time period had the index existed). There are frequently material differences between back-tested performance and actual results. Past performance — whether actual or back-tested — is no indication or guarantee of future performance.



^{*}Developed Markets countries in Europe include: Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the UK.

JUN 30, 2025 Index Factsheet


INDEX CHARACTERISTICS

	MSCI Europe Pharmaceuticals, Biotechnology & Life Sciences
Number of	26
Constituents	
	Mkt Cap (USD Millions)
Index	1,413,819.58
Largest	229,694.03
Smallest	3,624.04
Average	54,377.68
Median	16,936.51

TOP 10 CONSTITUENTS

	Country	Float Adj Mkt Cap (USD Billions)	Index Wt. (%)
NOVARTIS	CH	229.69	16.25
ROCHE HOLDING GENUSS	CH	228.07	16.13
NOVO NORDISK B	DK	222.75	15.76
ASTRAZENECA	GB	215.04	15.21
SANOFI	FR	107.14	7.58
GSK	GB	78.41	5.55
LONZA GROUP	CH	51.27	3.63
HALEON	GB	46.30	3.27
ARGEN X	BE	33.67	2.38
BAYER	DE	29.45	2.08
Total		1,241.79	87.83

FACTORS - KEY EXPOSURES THAT DRIVE RISK AND RETURN MSCI FACTOR BOX



MSCI FaCS



VALUE Relatively Inexpensive Stocks



LOW SIZE Smaller Companies



MOMENTUM Rising Stocks



QUALITY
Sound Balance Sheet Stocks



YIELD Cash Flow Paid Out




LOW VOLATILITY Lower Risk Stocks

MSCI FaCS provides absolute factor exposures relative to a


broad global index - MSCI ACWI IMI.

Neutral factor exposure (FaCS = 0) represents MSCI ACWI IMI.

SUB-INDUSTRY WEIGHTS



COUNTRY WEIGHTS





JUN 30, 2025 Index Factsheet

MSCI FACTOR BOX AND FaCS FRAMEWORK (Please refer to complete description of the MSCI FaCS methodology here)

MSCI FaCS is a standard method for evaluating and reporting the Factor characteristics of equity portfolios. MSCI FaCS consists of Factor Groups (e.g. Value, Size, Momentum, Quality, Yield, and Volatility) that have been extensively documented in academic literature and validated by MSCI Research as key drivers of risk and return in equity portfolios. These Factor Groups are constructed by aggregating 16 factors (e.g. Book-to-Price, Earnings/Dividend Yields, LT Reversal, Leverage, Earnings Variability/Quality, Beta) from the latest Barra global equity factor risk model, GEMLT, designed to make fund comparisons transparent and intuitive for use. The MSCI Factor Box, which is powered by MSCI FaCS, provides a visualization designed to easily compare absolute exposures of funds/indexes and their benchmarks along 6 Factor Groups that have historically demonstrated excess market returns over the long run.

ABOUT MSCI

MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. To learn more, please visit www.msci.com.

The information contained herein (the "Information") may not be reproduced or redisseminated in whole or in part without prior written permission from MSCI. The Information may not be used to verify or correct other data, to create any derivative works, to create indexes, risk models, or analytics, or in connection with issuing, offering, sponsoring, managing or marketing any securities, portfolios, financial products or other investment vehicles. Historical data and analysis should not be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information or MSCI index or other product or service constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy. Further, none of the Information or any MSCI index is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. MSCI ESG and climate ratings, research and data are produced by MSCI ESG Research LLC. MSCI Indexes, analytics and Real Estate are products of MSCI Inc. that utilize information from MSCI ESG Research LLC. MSCI Indexes are administered by MSCI Limited (UK) and MSCI Deutschland GmbH. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information. NONE OF MSCI INC. OR ANY OF ITS SUBSIDIARIES OR TISS OR THEIR DIRECT OR INDIRECT SUPPLIERS OR ANY THIRD PARTY INVOLVED IN MAKING OR COMPILING THE INFORMATION PROVIDER" MAKES ANY WARRANTIES OR REPRESENTATIONS AND, TO THE MAXIMUM EXTENT PERMITTED BY LAW, EACH INFORMATION PROVIDER HEREBY EXPRESSLY DISCLAIMS ALL IMPLIEDWARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. WITHOUT LIMITING ANY OF THE INFORMATION PROVIDER HAVE ANY LIABILITY REGARDING ANY OF THE INFORMATION PROVIDERS HAVE ANY LIABILITY REGARDING ANY OF THE INFORMATION PROVIDERS HAVE ANY LIAB

© 2025 MSCI Inc. All rights reserved.

